These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17236550)

  • 1. [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
    Xu JM; Li YM; Wang Y; Zhao CH; Yuan SJ; Yang WW; Li ZQ; Han Y; Azzariti A; Paradiso A
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):578-82. PubMed ID: 17236550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
    Azzariti A; Xu JM; Porcelli L; Paradiso A
    Biochem Pharmacol; 2004 Jul; 68(1):135-44. PubMed ID: 15183125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytotoxic effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with oxaliplatin on lung cancer cell line A549].
    Zhao CH; Yuan SJ; Wang Y; Ge FJ; Luo WD; Xu JM
    Ai Zheng; 2007 Dec; 26(12):1299-303. PubMed ID: 18076790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
    Kishida O; Miyazaki Y; Murayama Y; Ogasa M; Miyazaki T; Yamamoto T; Watabe K; Tsutsui S; Kiyohara T; Shimomura I; Shinomura Y
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):584-94. PubMed ID: 15723219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.
    Temmink OH; Hoebe EK; Fukushima M; Peters GJ
    Eur J Cancer; 2007 Jan; 43(1):175-83. PubMed ID: 17049227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
    Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
    J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
    Braun AH; Stark K; Dirsch O; Hilger RA; Seeber S; Vanhoefer U
    Anticancer Drugs; 2005 Nov; 16(10):1099-108. PubMed ID: 16222152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway.
    Sumitomo M; Asano T; Asakuma J; Asano T; Horiguchi A; Hayakawa M
    Clin Cancer Res; 2004 Jan; 10(2):794-801. PubMed ID: 14760103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.
    Premkumar DR; Arnold B; Pollack IF
    Mol Carcinog; 2006 May; 45(5):288-301. PubMed ID: 16550610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
    Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
    Hu YP; Patil SB; Panasiewicz M; Li W; Hauser J; Humphrey LE; Brattain MG
    Cancer Res; 2008 Oct; 68(19):8004-13. PubMed ID: 18829558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines.
    Miyata H; Sasaki T; Kuwahara K; Serikawa M; Chayama K
    Int J Oncol; 2006 Apr; 28(4):915-21. PubMed ID: 16525641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
    Gongora C; Candeil L; Vezzio N; Copois V; Denis V; Breil C; Molina F; Fraslon C; Conseiller E; Pau B; Martineau P; Del Rio M
    Cancer Biol Ther; 2008 Jun; 7(6):822-32. PubMed ID: 18340113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.